Advertisement
Research Article| Volume 343, P149-155, November 15, 2021

Download started.

Ok

Long term outcomes in patients with RF/RHD: Eight-year follow-up of HP-RF/RHD (Himachal Pradesh Rheumatic Fever/Rheumatic Heart Disease) registry in a Northern Indian state

Published:September 11, 2021DOI:https://doi.org/10.1016/j.ijcard.2021.09.014

      Highlights

      • Contemporary data on long term outcomes in patients with RF/RHD is limited.
      • The incidence of adverse outcomes is variable across countries with different socioeconomic states.
      • India contributes to about 40% of the global burden of RF/RHD.
      • The long term outcome in patients with RF/RHD have not been reported from India.
      • The HP-RF/RHD registry data of long term outcomes bridges this knowledge gap.

      Abstract

      Background

      The long-term outcome data in patients with rheumatic fever/rheumatic heart disease (RF/RHD) is limited. We report the cumulative incidence of adverse outcomes in a cohort of RHD patients from a northern state of India at a median follow-up of 5.4 years.

      Methods

      1714 patients with RF/RHD diagnosed using clinical and echocardiographic criteria were registered from 2011 to 2018, and their baseline clinical characteristics and treatment practices were recorded. Patients were followed up annually for a median of 5.4 years (range 1–8 years) for incident adverse outcomes. The cumulative incidence of adverse composite outcomes, all-cause mortality, hospitalization for heart failure, stroke, and/or peripheral embolism was estimated. The baseline clinical characteristics were explored to identify the potential risk predictors using a multivariate cox proportional hazard model.

      Results

      The cumulative incidence of adverse composite outcomes was 17.1% (15.3%–19.0%) at a median follow-up of 5.4 years. The predictors for the adverse composite outcomes (hazard ratio, 95% confidence interval) were age (1.03, 1.02–1.04), education status below primary level (1.60, 1.23–2.05), severe valvular heart disease (1.74, 1.36–2.23), NYHA class III/IV at enrollment (1.56, 1.18–2.07), right heart failure (4.48, 2.85–6.95), history of stroke and/or peripheral embolism (3.7, 1.5–9.2) and mitral balloon valvuloplasty (0.62, 0.40–0.96).

      Conclusions

      The incidence of adverse outcomes is substantial in patients with RF/RHD. Thus, early detection of high-risk patients and their risk management is needed to improve outcomes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Saxena A.
        • Desai A.
        • Narvencar K.
        • et al.
        Echocardiographic prevalence of rheumatic heart disease in Indian school children using World Heart Federation criteria - a multi site extension of RHEUMATIC study (the e-RHEUMATIC study).
        Int. J. Cardiol. 2017; 249: 438-442
        • Watkins D.A.
        • Johnson C.O.
        • Colquhoun S.M.
        • et al.
        Global, regional, and national burden of rheumatic heart disease, 1990–2015.
        N. Engl. J. Med. 2017; 377: 713-722
        • Negi P.C.
        • Sondhi S.
        • Rana V.
        • et al.
        Prevalence, risk determinants and consequences of atrial fibrillation in rheumatic heart disease: 6 years hospital based-Himachal Pradesh- Rheumatic Fever/Rheumatic Heart Disease (HP-RF/RHD) Registry.
        Ind. Heart J. 2018; 70: S68-S73https://doi.org/10.1016/j.ihj.2018.05.013
        • Negi P.C.
        • Mahajan K.
        • Rana V.
        • et al.
        Clinical characteristics, complications, and treatment practices in patients with RHD: 6-year results from HP-RHD registry.
        Glob. Heart. 2018; 13 (e2): 267-274
        • Kumar R.K.
        • Tandon R.
        Rheumatic fever & rheumatic heart disease: the last 50 years.
        Indian J. Med. Res. 2013; 137: 643-658
        • Zühlke L.
        • Engel M.E.
        • Karthikeyan G.
        • et al.
        Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).
        Eur. Heart J. 2015; 36 (1115-22a)https://doi.org/10.1093/eurheartj/ehu449
        • Karthikeyan G.
        • Zühlke L.
        • Engel M.
        • et al.
        Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study.
        Am. Heart J. 2012; 163 (e1): 535-540
        • Okello E.
        • Longenecker C.T.
        • Beaton A.
        • Kamya M.R.
        • Lwabi P.
        Rheumatic heart disease in Uganda: predictors of morbidity and mortality one year after presentation.
        BMC Cardiovasc. Disord. 2017; 17 (Published 2017 Jan 7): 20
        • Zühlke L.
        • Karthikeyan G.
        • Engel M.E.
        • et al.
        Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the global rheumatic heart disease registry (the REMEDY study).
        Circulation. 2016; 134: 1456-1466
        • He V.Y.
        • Condon J.R.
        • Ralph A.P.
        • et al.
        Long-term outcomes from acute rheumatic fever and rheumatic heart disease: a data-linkage and survival analysis approach.
        Circulation. 2016; 134: 222-232https://doi.org/10.1161/CIRCULATIONAHA.115.020966
        • Lawrence J.G.
        • Carapetis J.R.
        • Griffiths K.
        • Edwards K.
        • Condon J.R.
        Acute rheumatic fever and rheumatic heart disease: incidence and progression in the Northern Territory of Australia, 1997 to 2010.
        Circulation. 2013; 128: 492-501https://doi.org/10.1161/CIRCULATIONAHA.113.001477
        • Reményi B.
        • Wilson N.
        • Steer A.
        • et al.
        World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline.
        Nat. Rev. Cardiol. 2012; 9 (Published 2012 Feb 28): 297-309
        • Beaton A.
        • Carapetis J.
        The 2015 revision of the Jones criteria for the diagnosis of acute rheumatic fever: implications for practice in low-income and middle-income countries.
        Heart Asia. 2015; 7 (Published 2015 Aug 19): 7-11
        • Zoghbi W.A.
        • Enriquez-Sarano M.
        • Foster E.
        • et al.
        Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.
        J. Am. Soc. Echocardiogr. 2003; 16: 777-802https://doi.org/10.1016/S0894-7317(03)00335-3
        • Baumgartner H.
        • Hung J.
        • Bermejo J.
        • et al.
        Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice [published correction appears in J Am Soc Echocardiogr. 2009 May;22(5):442].
        J. Am. Soc. Echocardiogr. 2009; 22: 1-102
        • Nishimura R.A.
        • Otto C.M.
        • Bonow R.O.
        • et al.
        2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014 Jun 10;129(23):e650].
        Circulation. 2014; 129: 2440-2492https://doi.org/10.1161/CIR.0000000000000029
        • Iung B.
        • Duval X.
        Infective endocarditis: innovations in the management of an old disease.
        Nat. Rev. Cardiol. 2019; 16: 623-635https://doi.org/10.1038/s41569-019-0215-0
        • Pelajo C.F.
        • Lopez-Benitez J.M.
        • Torres J.M.
        • de Oliveira S.K.
        Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever.
        Pediatr. Rheumatol. Online J. 2010; 8 (Published 2010 Jul 26): 22
        • Liaw J.Y.
        • White A.V.
        • Gorton S.
        • Axford-Haines L.
        Lessons to be learned: using National Immunisation strategies to improve adherence to acute rheumatic fever secondary prophylaxis.
        J. Paediatr. Child Health. 2019; 55: 1170-1176https://doi.org/10.1111/jpc.14596
        • Kevat P.M.
        • Reeves B.M.
        • Ruben A.R.
        • Gunnarsson R.
        Adherence to secondary prophylaxis for acute rheumatic fever and rheumatic heart disease: a systematic review.
        Curr. Cardiol. Rev. 2017; 13: 155-166https://doi.org/10.2174/1573403X13666170116120828